ePlus Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Fourth Quarter And Full Year Gross Profit And Gross Margin Improved Year Over Year; Double Digit EPS Growth for Fourth Quarter Fourth Quarter Fiscal Year 2025• Net sales decreased 10.2% to $498.1 million from last year's fourth quarter; Technology business net sales decreased 10.4% to $487.2 million; service revenues increased 33.0% to $104.9 million.• Technology […]

Stagwell Inc. (STGW) Reports Equity Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stagwell Inc. (the “Company”) announced today the grant of equity inducement awards. Effective May 20, 2025, the Company granteda total of 45,832 restricted stock unitsto four new employees. Each restricted stock unit represents the right to receive one share of the Company's Class A common stock. The restricted stock units will vest in two installments,

Nukkleus Comments on Trump Administration’s Further Commitment to Build a “Golden Dome”

Nukkleus Inc. (NASDAQ: NUKK), which is pursuing a highly disciplined global M&A strategy in the Aerospace & Defense (A&D) industry, today commented on the recent announcement by the Trump Administration to invest an initial $25 billion in building a “Golden Dome” missile defense shield. The plan to build a Golden Dome aims to counter growing

LIONSGATE REPORTS RESULTS FOR FOURTH QUARTER FISCAL 2025

Revenue was $1.1Billion, up 22%Year Over Year Net Income Attributable to Shareholders was $21.9Millionor $0.10Diluted Earnings Per Share Adjusted Net Income Attributable to Shareholders was $60.9Million or $0.21Adjusted Diluted Earnings Per Share Operating Income was Up Significantly to $94.2 Million Adjusted OIBDAwas Up 49% to $138.3 Million Motion Picture Segment Profit and Studio Adjusted OIBDA

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences: TD Cowen's 6th Annual Oncology Innovation Summit: Insights from ASCO & EHAFormat: Fireside ChatDate: Tuesday, May 27, 2025Time: 1:00 p.m. ET

China Liberal Education Holdings Limited Receives Additional Nasdaq Staff Determination Letter of Delinquency

China Liberal Education Holdings Limited (“China Liberal” or the “Company”) (Nasdaq:CLEU), aChina-based company that provides technological consulting services for smart campus solutions and other educational services, today announced that on May21, 2025, it received an additional staff determination notice (the “Additional Staff Determination Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC

TDS announces second quarter 2025 dividends

The board of directors of Telephone and Data Systems, Inc. (NYSE:TDS), a leading provider of telecommunications services, has declared second quarter 2025 dividends on its Common Shares, Series A Common Shares, Series UU Preferred Shares and Series VV Preferred Shares. — TDS is paying a quarterly dividend of $0.04 per Common Share and Series A

ZBIO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

ZBIO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit GlobeNewswire May 22, 2025 SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas

Epsilon Announces 2025 AGM Results

(NasdaqGM:EPSN), HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) — Epsilon Energy Ltd. (“Epsilon” or the “Company“) (NASDAQ: EPSN) is pleased to announce that all the nominees listed in its Proxy Statement, Schedule 14A dated on April 17, 2025 were elected as directors of Epsilon, until the next annual meeting of shareholders. The detailed results of the

Cavco Industries Reports Fiscal 2025 Fourth Quarter and Year End Results

(NASDAQ:CVCO), PHOENIX, May 22, 2025 (GLOBE NEWSWIRE) — Cavco Industries, Inc. (Nasdaq: CVCO) today announced financial results for the fourth quarter and fiscal year ended March 29, 2025. Quarterly Highlights Net revenue of $508 million up 21% from $420 million in the prior year quarter. Gross profit as a percentage of Net revenue was 22.8%

Scroll to Top